Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
This study is a retrospective real-world study to evaluate the efficacy of Osimertinib for patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer|EGFR Exon20 Insertion Mutations
DRUG: Osimertinib
1.Real world Objective Response Rate (rwORR), March 2017 to May 2022
Real world Duration of Response（rwDOR）, From March 2017 to May 2022|Real world Disease Control Rate（rwDCR）, From March 2017 to May 2022|Real world Progression Free Survival（rwPFS）, From March 2017 to May 2022
This is a multicenter, retrospective observational real-world study, which evaluates the efficacy of Osimertinib, between 2017 and 2022, in patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer. This study serves as the external control for a single arm phase II trial on JMT101 combined with Osimertinib in patients with Non-Small Cell Lung Cancer. The primary outcome measure is objective response rate (ORR).